Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 4/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684623 | 0.94 | EPHX2 (0.40) | HDAC2EPHX2USP2SMN1; SMN2CA14 | |
| SCHEMBL5567244 | 0.88 | HDAC2 (0.39) | HDAC2EPHX2PIK3R1PIK3CACYP11B2 | |
| SCHEMBL1586974 | 0.82 | EPHX2 (0.43) | HDAC2EPHX2USP2SMN1; SMN2HDAC1 | |
| SCHEMBL5571339 | 0.82 | NAMPT (0.34) | EPHX2 | |
| SCHEMBL15286297 | 0.81 | USP2 (0.41) | HDAC2EPHX2USP2SMN1; SMN2CA14 | |
| SCHEMBL13549258 | 0.81 | USP2 (0.41) | HDAC2EPHX2USP2SMN1; SMN2CA14 | |
| SCHEMBL19331998 | 0.79 | CNR2 (0.38) | HDAC2EPHX2PIK3R1PIK3CAUSP2 | |
| SCHEMBL23214690 | 0.79 | USP2 (0.39) | HDAC2EPHX2USP2SMN1; SMN2RORC | |
| SCHEMBL19331794 | 0.78 | PIK3R1 (0.36) | HDAC2EPHX2PIK3R1PIK3CAUSP2 | |
| SCHEMBL19331746 | 0.78 | JAK2 (0.41) | PIK3R1PIK3CAJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202246-B2 | Spiro-rifamycin derivatives targeting RNA polymerase | CUMBRE PHARMACEUTICALS INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050277633-A1 | E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria | CUMBRE INC. (US) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277633-A1 | E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria | RIF1, MAPRE1, MAPRE2 | HDAC2 25/4885EPHX2 3471/4885PIK3R1 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.